NCT03438461View on ClinicalTrials.gov

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 9, 2018

Primary Completion Date

May 30, 2018

Study Completion Date

May 30, 2018

Conditions
Healthy
Interventions
DRUG

Seltorexant 40 mg

Seltorexant 40 mg as two tablets of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 1.

DRUG

Seltorexant 20 mg

Seltorexant as a tablet of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 2.

Trial Locations (1)

84124

PRAHS, Salt Lake City

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03438461 - A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions | Biotech Hunter | Biotech Hunter